Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast
Cats develop dementia similarly to humans with Alzheimer's disease.
Scientists hope their findings lead to new treatments for both humans and our feline friends.
For more, we spoke to the lead author, Dr Robert McGeachan, at the University of Edinburgh's Royal School of Veterinary Studies.
A swarm of jellyfish forced the shutdown of France's largest nuclear power plant, Gravelines.
But how unusual is this event?
And, Reddit blocks the Internet Archive's Wayback Machine from archiving large portions of its site.
Also in this episode:
-How blowing through a conch shell could alleviate the symptoms of obstructive sleep apnoea
-Lola Young urges Keir Starmer to block Rosebank oil and gas development projects
-Natalie the Nerd builds a transparent GameBoy Colour
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
The global recombinant human hair keratin protein market is growing quickly as more people seek effective hair health solutions and advanced wound healing treatments, says a study published by Towards Healthcare a sister firm of Precedence Research. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The global recombinant human hair keratin protein market is on a strong growth trajectory, with revenues expected to climb into the hundreds of millions by 2034. This momentum is being fueled by a rising focus on hair health, a noticeable increase in bleeding disorder cases, and a wave of fresh investments pouring into biotechnology. Together, these factors are creating fertile ground for innovation and demand across multiple industries. Companies in North America, Asia-Pacific, and Europe are actively investing in research, driving innovations, and forming partnerships to open new market opportunities. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the recombinant human hair keratin protein market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Market Overview & Potential Recombinant human hair keratin protein is a lab-engineered protein that replicates the structure and function of natural keratin in human hair. It is produced via recombinant DNA technology, resulting in a highly controlled and pure form of keratin that differs from traditional extracts. This makes it a valuable material for applications such as wound healing and hair care. Conventional keratin extraction methods can be inconsistent and may not yield pure products, whereas recombinant production ensures greater purity and enables precise control over the protein's amino acid sequence and structure, resulting in more predictable properties. Top Countries in Recombinant Human Hair Keratin Protein Market: United States Contribution: Leading the global market with strong demand for medical-grade recombinant keratin, supported by a robust biotech ecosystem and healthcare infrastructure. Strength: Advanced R&D capabilities and regulatory support for therapeutic and regenerative applications. China Contribution: Fastest-growing market, fueled by a rapidly expanding cosmetics and personal care sector. Strength: Strong domestic production capabilities, rising consumer awareness, and increasing investment in biotech innovations. Germany Contribution: Key contributor in Europe, especially in high-purity recombinant keratin for medical and cosmetic formulations. Strength: Expertise in biotechnology and demand for premium, high-performance personal care products. France Contribution: Strong market for cosmetic applications, particularly in haircare and skincare products incorporating natural bioactive ingredients. Strength: Sophisticated beauty industry and preference for sustainable, biologically derived ingredients. India Contribution: Emerging player in both medical and cosmetic applications of recombinant keratin. Strength: Large population base, rising demand for advanced hair and skin treatments, and growing domestic manufacturing activity. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growth Potential Responsible for The Growth of The Recombinant Human Hair Keratin Protein Market? The growth of the market is driven by the growing application in the biomedical field due to its biocompatibility, ability to promote cell growth, and biodegradability, which makes it ideal for various medical uses, driving the growth. The key applications, like tissue regeneration, drug delivery systems, and wound healing, are supporting the growth of the market. Other key drivers are biotechnology research due to the growing biotechnology sector, in personal care and cosmetics, and sustainable and ethical sourcing. Increasing incidence of chronic diseases, and government initiatives in R&D in life sciences research and development. What Are the Growing Trends Associated with the Recombinant Human Hair Keratin Protein Market? The technological advancements like innovation in synthetic biology and demonstration technology for the development of new and tailored properties, and more efficient production methods. Rising demand in the cosmetic sector for the development of hair care products for improving the shine, strengthening the damaged hair, and reducing the frizz increases the demand for the product. The growing biomedical applications, like in wound healing, tissue engineering, and drug delivery, fuel the demand for the product, supporting the growth. Shift towards sustainable and ethical products, like growing demand and interest in vegan and plant-based keratins, improves the market growth of the market. Increasing awareness and adoption due to the benefits offered and availability of the products make it a preferred choice, and increase the growth. What Is the Growing Challenge in the Recombinant Human Hair Keratin Protein Market? However, the recombinant human hair keratin protein market faces challenges including production issues, consistency concerns, and consumer perceptions. Although recombinant technology provides advantages like higher purity and specific amino acid composition, it also risks problems like misfolding, aggregation, and low yields. Additionally, high production costs, especially due to specialized equipment and chemicals, can hinder market growth. Consumer preferences for natural or plant-based products, along with safety and efficacy concerns regarding keratin treatments, could also limit market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Recombinant Human Hair Keratin Protein Market in 2024? North America led the recombinant human hair keratin protein market in 2023. Growth is driven by increased investments, collaborations, key industry players, and advanced R&D activities. The US and Canada are the primary markets, with companies like Novus Biologicals, Abcam Ltd., PROGEN, and OriGene contributing significantly. US government initiatives to promote biotech research further boost the market, complemented by over 130 recombinant proteins approved by the US FDA for clinical use. In the UK, industries are exploring innovative methods to enhance hair growth, quality, and reduce hair fall using recombinant human hair keratin protein. Additionally, rising awareness about hair health is fueling demand for these products. What Made Asia Pacific Significantly Grow in The Recombinant Human Hair Keratin Protein Market in 2024? Asia-Pacific is expected to grow the fastest in the recombinant human hair keratin protein market during the forecast period. Market growth is driven by increasing research and development activities, rising government funding, a growing number of bleeding disorder cases, favorable infrastructure, and lower costs. Recombinant keratin has been shown to promote skin wound healing and improve blood clotting. In China, about 65,000 people suffer from hemophilia, while India has the second-largest number of hemophilia cases worldwide, with 136,000 patients. The demand for products that support hair growth and reduce hair loss is rapidly increasing in China, South Korea, and Japan. Companies like Tsubaki use recombinant human keratin to develop luxurious hair treatments that attract beauty-conscious consumers. Become a valued research partner with us - Recent Developments In July 2024, Yuhan Corp, a South Korean pharmaceutical company, signed a comprehensive R&D collaboration agreement with ProGen. The collaboration was made to strengthen next-generation biologics and drug development research. In April 2024, Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific. The agreement will distribute Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, reagents, and enzymes, to laboratories and research institutions across Europe. Browse More Insights of Towards Healthcare: The global GMP grade cytokines market is valued at USD 2.54 billion in 2024, expected to rise to USD 2.79 billion in 2025, and anticipated to reach approximately USD 6.48 billion by 2034. This represents a steady growth trajectory at a CAGR of 9.84% from 2025 to 2034. The global recombinant proteins market is estimated at USD 3.36 billion in 2025 and is forecasted to climb to around USD 8.08 billion by 2034, expanding at a CAGR of 10.24% over the forecast period. The recombinant lysyl endopeptidase market was valued at USD 38 million in 2023 and is projected to reach USD 67.06 million by 2034, growing at a CAGR of 5.3% between 2024 and 2034. The global hair transplant market stands at USD 7.33 billion in 2024, rising to USD 8.87 billion in 2025, with projections indicating a surge to nearly USD 49.44 billion by 2034—signaling rapid expansion. The hair treatment drug market was worth USD 1.4 billion in 2023 and is anticipated to grow to USD 2.99 billion by 2034, recording a CAGR of 7.14% during 2024–2034. The global host cell protein testing market is valued at USD 2.37 billion in 2024, estimated to increase to USD 2.56 billion in 2025, and forecasted to hit USD 5.19 billion by 2034, with an expected CAGR of 8.17% from 2025 to 2034. The global protein expression technology market is pegged at USD 2.85 billion in 2024, projected to rise to USD 3.05 billion in 2025, and likely to reach USD 5.58 billion by 2034, reflecting a CAGR of 6.94% over the forecast timeline. The global proteinase K market is valued at USD 4.82 billion in 2024, forecasted to grow to USD 5.23 billion in 2025, and set to reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% between 2025 and 2034. The global cell-free protein expression market is valued at USD 315.03 million in 2024, expected to grow to USD 342.25 million in 2025, and projected to hit USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market is calculated at USD 375.3 billion in 2024, projected to grow to USD 401.89 billion in 2025, and expected to reach USD 740.07 billion by 2034, advancing at a CAGR of 7.08% over the forecast period. Recombinant Human Hair Keratin Protein Market Key Players Abcam Limited Abbexa, Ltd. Bon Opus Biosciences Creative Diagnostics MyBioSource, Inc. Novus Biologicals OriGene PROGEN ProSpec Wuhan Huamei Biotech Co., Ltd. Regions Covered North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Causes, symptoms and how to prevent chikungunya - as cases rise in the UK
Health authorities have warned of a "worrying increase" in cases of a mosquito-borne infection in people returning to the UK from abroad. of chikungunya were reported between January and June 2025 - more than double the 27 cases reported in the same period last year, the UK Health Agency (UKHSA) said. Data released by the agency also revealed three cases of oropouche virus, marking the first time the virus has been reported in the UK. Here is everything you need to know about both viruses, from symptoms to prevention and what could be behind the surge in cases. What is chikungunya? Chikungunya is a disease caused by a virus of the same name. It was first identified following an outbreak in Tanzania in 1952. The name is derived from a word in the Tanzanian language Makonde, and means "that which bends up", owing to the joint pain it can cause. It is spread by mosquito bites, specifically from yellow fever and tiger mosquitoes, in tropical and subtropical regions. What are the symptoms? Typical symptoms include fever, muscle pain, nausea, fatigue and a rash. The UKHSA says joint pain can persist for months or even years, with up to 12% of people still experiencing discomfort three years after infection. The majority of people who become infected recover within one to two weeks without needing medical attention. Serious complications are uncommon, and only very rare cases are fatal. Babies or elderly people with other underlying illnesses are the most vulnerable. The two mosquitoes known to transmit the disease, yellow fever and tiger, are not currently found in the UK. How does oropouche virus differ? Oropouche virus is spread predominantly by midge bites rather than mosquito bites. While bites from both insects can cause red itchy lumps on the skin, mosquito bites are generally larger and more painful, while midge bites are smaller and may last longer. Symptoms can be similar to chikungunya, and include joint paint, headache, chills, nausea and high fever. The UKHSA says anyone who becomes unwell with these symptoms after travelling should seek "urgent medical advice". Where can you catch the viruses? Regular outbreaks of chikungunya occur in Africa, Asia and the Americas, with occasional smaller instances in Europe. The UKHSA said the majority of the 73 reported cases from the first six months of this year reported travelling to Sri Lanka, India and Mauritius. The cases were linked to local outbreaks in the Indian Ocean region. As of last month, there have been about 240,000 cases of chikungunya - and 90 deaths - in 16 countries, according to the European Centres for Disease Prevention and Control (ECDC). Meanwhile, all the UK cases of oropouche virus were associated with travel to Brazil. Last year, 44 cases were reported in several European countries including Spain, Italy, France, Germany, Austria, Sweden and the Netherlands, according to the ECDC. China is currently experiencing the ever documented in the country, according to Cesar Lopez-Camacho of the University of Oxford. More than 7,000 cases have been reported since June, with 90% of those concentrated in Guangdong province, which borders Hong Kong. How to prepare before travelling Dr Philip Veal, a consultant in public health at UKHSA said it is "essential" for people to take precautions against mosquito bites when travelling. "Simple steps, such as using insect repellent, covering up your skin and sleeping under insecticide-treated bed nets can greatly reduce the risk," he said. Checking the latest health advice on your destination before you travel is also recommended. The LSHTM added that people can do the following to reduce exposure to mosquito and midge bites:• Fit screens to windows and doors;• Avoid peak activity during dusk and dawn;• Get rid of any standing water where mosquitoes breed. There are also two vaccines for chikungunya approved for use in the UK: IXCHIQ, for people aged 18 to 59 and Vimkunya, for individuals 12 years and older. Both are available to buy privately from travel clinics after an assessment by a healthcare professional. Read more from Sky News: What's behind the increase in cases? The number of outbreaks of chikungunya has increased since 2000, Robert Jones, an assistant professor at the London School of Hygiene and Tropical Medicine (LSHTM) said. Mr Jones put this boom partly down to climate change and urban expansion. Dr Yang Liu, another professor at LSHTM, said the outbreak in China is not totally unexpected, but highlights the manifestation of a known risk, as yellow fever and tiger mosquitoes have been present in the area for many years.
Medscape
an hour ago
- Medscape
Safety Body Warns Over Post-Discharge Information Gaps
Communication failures between hospitals and community services after patient discharge can lead to serious medication-related harm, a new report has warned. The Health Services Safety Investigations Body (HSSIB) found that gaps in patient records, poor information sharing, and insufficient post-discharge support can delay or prevent medication being taken, with potentially life-threatening consequences. Case Study: Missed Insulin After Discharge The investigation examined the case of a 53-year-old man whose diabetes medication was changed during a hospital stay. Although he received some education on self-administering insulin, he later said he struggled to remember the instructions. A referral for district nursing support was made via his GP, but the district nursing team was not informed. Seventeen days after discharge, he told a nurse that he had not been taking insulin. His glucose levels were dangerously high, leading to an emergency hospital readmission. Key Failings Identified The HSSIB identified several failings: Conflicting records on admission made it unclear whether the patient had been taking diabetes medication. No documented evidence confirmed his ability to self-administer insulin after discharge education. Communication about the need for district nursing support was inconsistent between hospital teams and community services, and no specific support for insulin administration was arranged. The patient was discharged with two insulin pens, one of which was unnecessary, causing him confusion. District nursing demand often exceeded capacity, limiting visit times. Multiple providers used incompatible electronic patient record systems, preventing the sharing of critical information. Recommendations for Safer Discharges The report calls for local-level learning prompts covering hospital care, discharge planning, and community follow-up to prevent similar risks. It stressed the importance of ensuring patients are confident in managing their medication before leaving hospital and improving interoperability between hospital and community electronic systems. 'A Matter of Patient Safety' Rebecca Doyle, safety investigator at HSSIB, said that improving information flow and patient support at discharge is more than an administrative task. 'It's a matter of patient safety,' she said. 'While individual cases can be complex, this incident clearly highlighted persistent challenges with information sharing – an issue we continue to see in investigations that explore communication and the interaction of digital systems. This information sharing is critical to keep people safe at home, managing their medical conditions, and avoiding readmission to hospital.' The report is the third and final in a series of HSSIB investigations exploring why medications intended to be given to patients were not given. Priscilla Lynch is a freelance writer for Medscape, with over 20 years' experience covering medicine and healthcare. She has a master's in journalism and recently undertook a Health Innovation Journalism Fellowship with the International Center for Journalists.
